Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) announced securement of the favorable opinion of the Food and Drug Administration (FDA) for the continuation of an optimized preclinical development plan relating to BBDF-101 in a bid to achieve IND status and begin clinical trials of BBDF-101 with a long exposure time (24 months) pending approval.
